111 filings
Page 4 of 6
8-K
4a0cf x8i3vdm9h
16 May 22
Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments
9:10am
S-8
5pzq8x4v
6 May 22
Registration of securities for employees
5:00pm
8-K
mej0l
31 Mar 22
Virpax Pharmaceuticals Reports 2021 Year-End Results
9:05am
8-K
jssmrvi u15wms
15 Mar 22
Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement
4:30pm
8-K
oomi2d5ej84a51b4
15 Nov 21
Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments
12:00am
POS EX
7tdo1m57a9al2bg
15 Sep 21
Additional exhibits for listing
4:31pm
424B4
f1ypbt32n
15 Sep 21
Prospectus supplement with pricing info
4:31pm
EFFECT
fs6w0cfdos ox1mbku
15 Sep 21
Notice of effectiveness
12:16am
FWP
n3bdiveouv5yhvk7k
10 Sep 21
Free writing prospectus
12:00am
CORRESP
9f5de l60k8lh8
9 Sep 21
Correspondence with SEC
12:00am
UPLOAD
7xaq4a9
9 Sep 21
Letter from SEC
12:00am
CORRESP
3x66t
9 Sep 21
Correspondence with SEC
12:00am
DRS
ut0c7fcq
1 Sep 21
Draft registration statement
12:00am
8-K
xbp2t
10 Aug 21
Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent Developments
9:05am
8-K
on54 b30kgyoerv5v66
30 Jul 21
Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board
9:15am
8-K
z3ewgt5
18 May 21
Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments
8:11am